Janux Therapeutics insider trades 3,333 JANX shares and options

Rhea-AI Filing Summary

Janux Therapeutics (JANX) reported an insider equity transaction by its Chief Business Officer. On 11/14/2025, the officer exercised a stock option for 3,333 shares of common stock at $10.59 per share and on the same date sold 3,333 shares at $30 per share. After these transactions, the officer beneficially owned 84,974 shares of Janux common stock directly and 118,101 stock options. The sale was conducted under a Rule 10b5-1 trading plan adopted on 09/30/2024. The filing also notes prior acquisitions of 1 share on 11/15/2024 and 2,834 shares on 05/15/2025 through the company’s 2021 Employee Stock Purchase Plan.

Insider Trade Summary

Exercise and Sale: 3,333 shares ($65K approx. pre-tax spread)

Exercise and Sale 3 txns

Insider Meyer Andrew Hollman

Role Chief Business Officer

Sold 3,333 shs ($100K)

Approx. gross sale proceeds $100K

Approx. exercise cost $35K

Approx. pre-tax spread $65K

Type	Security	Shares	Price	Value
Exercise	Stock Option (right to buy)	3,333	$0.00	$0.00
Exercise	Common Stock	3,333	$10.59	$35K
Sale	Common Stock	3,333	$30.00	$100K

Holdings After Transaction: Stock Option (right to buy) — 118,101 shares (Direct); Common Stock — 84,974 shares (Direct)

Footnotes (3)

1. F1. Includes 1 share acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2024 and 2,834 shares acquired under the Plan on May 15, 2025.
2. F2. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.
3. F3. Immediately exercisable.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Accepted by SEC EDGAR 11/14/2025 - 08:00 PM Learn about SEC filing dates

FAQ

What insider transaction did Janux Therapeutics (JANX) disclose in this Form 4?

The filing reports that the Chief Business Officer of Janux Therapeutics (JANX) exercised a stock option for 3,333 shares at $10.59 per share and sold 3,333 shares of common stock at $30 per share on 11/14/2025.

How many Janux Therapeutics (JANX) shares does the officer own after the reported transaction?

Following the transactions, the officer beneficially owned 84,974 shares of Janux Therapeutics common stock directly and 118,101 stock options.

Was the Janux Therapeutics (JANX) share sale under a Rule 10b5-1 plan?

Yes. The 3,333-share sale was made pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 09/30/2024.

What type of derivative security did the Janux Therapeutics (JANX) officer exercise?

The officer exercised a stock option (right to buy) covering 3,333 shares of Janux common stock at an exercise price of $10.59 per share, with an expiration date of 05/13/2031.

What prior share acquisitions under Janux’s 2021 Employee Stock Purchase Plan are disclosed?

The filing notes that the reported holdings include 1 share acquired on 11/15/2024 and 2,834 shares acquired on 05/15/2025 under Janux’s 2021 Employee Stock Purchase Plan.

Who is the reporting person in this Janux Therapeutics (JANX) Form 4 and what is their role?

The reporting person is an officer of Janux Therapeutics, Inc. serving as the company’s Chief Business Officer.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Meyer Andrew Hollman

(Last) (First) (Middle)

C/O JANUX THERAPEUTICS, INC.

10955 VISTA SORRENTO PARKWAY, SUITE 200

(Street)

SAN DIEGO CA 92130

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Janux Therapeutics, Inc. [ JANX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
11/14/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/14/2025		M		3,333	A	$10.59	88,307(1)	D
Common Stock	11/14/2025		S(2)		3,333	D	$30	84,974	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$10.59	11/14/2025		M			3,333	(3)	05/13/2031	Common Stock	3,333	$0	118,101	D

Explanation of Responses:

1. Includes 1 share acquired under the Issuer's 2021 Employee Stock Purchase Plan (the "Plan") on November 15, 2024 and 2,834 shares acquired under the Plan on May 15, 2025.

2. The shares were sold pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 30, 2024.

3. Immediately exercisable.

	/s/ James Pennington, Attorney-in-Fact	11/14/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.